- Benign Prostatic Hyperplasia
- Hormone Therapy
- Genomic Testing
- Next-Generation Imaging
- UTUC
- OAB and Incontinence
- Genitourinary Cancers
- Kidney Cancer
- Men's Health
- Pediatrics
- Female Urology
- Sexual Dysfunction
- Kidney Stones
- Urologic Surgery
- Bladder Cancer
- Benign Conditions
- Prostate Cancer
Investigational BPH drug shows promise in phase II trial
Patients with BPH who were treated with the investigational drug NX-1207 showed a total pooled mean improvement of 9.35 points in the primary outcome endpoint of AUA Symptom Score values at 3 months, researchers from Nymox Pharmaceutical Corp. reported.
Patients with BPH who were treated with the investigational drug NX-1207 showed a total pooled mean improvement of 9.35 points in the primary outcome endpoint of AUA Symptom Score values at 3 months, researchers from Nymox Pharmaceutical Corp. reported. The results reached statistical significance when compared with placebo (p=.017).
Treated patients also showed an overall significant reduction in mean prostate volume of 11.7% (6.84 grams; p=.02). The double-blind, placebo-controlled study included 175 patients from 43 U.S. clinical trial sites.
Patients in the trial reported no significant sexual side effects or other serious side effects.
